Jazz Pharmaceuticals leads structurally, with growth as the clearest single gap between the two profiles. The remaining gap is narrow enough that the comparison remains open to different readings. On the market side, Jazz Pharmaceuticals is in better shape — its trend is intact while Medtronic's trend has broken down. That puts structure and market broadly in agreement — Jazz Pharmaceuticals's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
The comparison is mainly decided in growth, with the rest of the profile carrying less weight. Jazz Pharmaceuticals plc leads by 8 points on the overall comparison score.
This pair is matched through long-term financial trajectory similarity within the selected peer universe.
The pair shares a valid long-term profile match, but the trajectories are not especially close.
The strongest overlap appears in investment intensity and revenue stability.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The clearest separation appears in growth.
Left means cheaper relative valuation. Higher means stronger structure.
Jazz Pharmaceuticals plc looks stronger on relative valuation, while the broader price setup remains mixed.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where JAZZ and MDT each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The current lead is backed by a stronger multi-year growth trajectory.
Medtronic plc still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.
Growth clearly separates the pair, while the broader read stays strong rather than one-way.
Break down the JAZZ vs MDT comparison across all dimensions with the full interactive tool.
Explore how JAZZ and MDT each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.